HVB MINI FUTURE BULL - ASTRAZENECA | Real-time Bid/Ask 09:31:00 2024-04-29 am EDT | ||
| 6.46 EUR / 6.47 EUR | +2.62% |
|
| Current month | +31.52% | ||
| 1 month | +41.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 6.47 | +2.70% | 0 |
| 24-04-26 | 6.3 | +0.80% | 0 |
| 24-04-25 | 6.25 | +14.05% | 0 |
| 24-04-24 | 5.48 | +2.24% | 0 |
| 24-04-23 | 5.36 | -1.47% | 0 |
Delayed Quote Börse Stuttgart
Last update April 29, 2024 at 08:59 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TXZ |
| ISIN | DE000HR5TXZ9 |
| Date issued | 2021-02-25 |
| Strike | 6,634 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.85 € |
|---|---|
| Lowest since issue | 0.95 € |
| Spread | 0.01 € |
| Spread % | 0.16% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.3
USD
Spread / Average Target
+10.02%
- Stock Market
- Certificates
- Certificat
